Apstatin 

Apstatin is a potent aminopeptidase P (APP) inhibitor with K_i values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin shows cardioprotection^[1][2].

IC₅₀: 2.6 µM (rat APP); 0.64 µM (human APP)^[1]

Apstatin (1 mg/kg; i.v.; 5 min before ischaemia) reduces myocardial infarct size (IS) in acute myocardial ischaemia model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

459.54

C₂₃H₃₃N₅O₅

160470-73-5

C[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@@H](O)[C@H](N)CC3=CC=CC=C3)=O)CCC2)=O)CCC1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wolfrum S, et al. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol. 2001 Sep;134(2):370-4.  [Content Brief]

  [2]. Maggiora LL, et al. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42(13):2394-402.  [Content Brief]